• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of cviPermissionsJournals.ASM.orgJournalAEM ArticleJournal InfoAuthorsReviewers
Clin Vaccine Immunol. Sep 2007; 14(9): 1102–1107.
Published online Aug 1, 2007. doi:  10.1128/CVI.00386-06
PMCID: PMC2043309

Cervicovaginal Levels of Lactoferrin, Secretory Leukocyte Protease Inhibitor, and RANTES and the Effects of Coexisting Vaginoses in Human Immunodeficiency Virus (HIV)-Seronegative Women with a High Risk of Heterosexual Acquisition of HIV Infection[down-pointing small open triangle]

Abstract

Innate immune factors in mucosal secretions may influence human immunodeficiency virus type 1 (HIV-1) transmission. This study examined the levels of three such factors, genital tract lactoferrin [Lf], secretory leukocyte protease inhibitor [SLPI], and RANTES, in women at risk for acquiring HIV infection, as well as cofactors that may be associated with their presence. Women at high risk for HIV infection meeting established criteria (n = 62) and low-risk controls (n = 33) underwent cervicovaginal lavage (CVL), and the CVL fluid samples were assayed for Lf and SLPI. Subsets of 26 and 10 samples, respectively, were assayed for RANTES. Coexisting sexually transmitted infections and vaginoses were also assessed, and detailed behavioral information was collected. Lf levels were higher in high-risk (mean, 204 ng/ml) versus low-risk (mean, 160 ng/ml, P = 0.007) women, but SLPI levels did not differ, and RANTES levels were higher in only the highest-risk subset. Lf was positively associated only with the presence of leukocytes in the CVL fluid (P < 0.0001). SLPI levels were lower in women with bacterial vaginosis [BV] than in those without BV (P = 0.04). Treatment of BV reduced RANTES levels (P = 0.05). The influence, if any, of these three cofactors on HIV transmission in women cannot be determined from this study. The higher Lf concentrations observed in high-risk women were strongly associated with the presence of leukocytes, suggesting a leukocyte source and consistent with greater genital tract inflammation in the high-risk group. Reduced SLPI levels during BV infection are consistent with an increased risk of HIV infection, which has been associated with BV. However, the increased RANTES levels in a higher-risk subset of high-risk women were reduced after BV treatment.

A number of studies suggest that innate factors in mucosal secretions from a variety of sources are capable of modifying human immunodeficiency virus type 1 (HIV-1) infection in vitro. Secretory leukocyte protease inhibitor [SLPI], a serine protease inhibitor which can be found in oral and genital tract secretions, appeared to inhibit in vitro infection with HIV in several studies (13, 19, 23, 24), although this effect was not consistently found (27). The antiviral effect of SLPI appears to occur in both monocytes and lymphocytes after viral binding to the host cell but before reverse transcription (20), possibly through inhibition of HIV interaction with annexin II (18).

Lactoferrin [Lf], a protein also found in a variety of mucosal secretions, has similarly been shown to have anti-HIV properties (4, 21, 28). RANTES has been demonstrated to be the natural ligand for CCR5 and to be capable of inhibiting HIV infection of macrophages in vitro (2, 5, 7). Both Lf and SLPI have been identified in saliva, and SLPI in an infant's saliva may play a role in mitigating mother-to-child transmission of HIV (10, 11). SLPI has recently been shown to play a role in the regulation of immunoglobulin class switching at mucosal surfaces (29).

A recent study of commercial sex workers (CSW) who are exposed to HIV but remain uninfected has found elevated RANTES expression in cervical lymphocytes compared with low-risk controls (12) and in HIV-resistant CSW compared to non-HIV-infected CSW (14). There is a paucity of data regarding Lf and SLPI levels in the vaginal mucosal secretions in women with a low or increased risk of acquiring HIV infection that might support a role for these innate antimicrobial factors in vivo, and there has been no study to date which specifically investigated the effect of treatment of BV on genital tract RANTES levels. The present study examined Lf, SLPI, and RANTES levels in cervicovaginal secretions from women with a low or high risk of acquiring HIV infection.

(This paper was presented as a poster on 14 August 2006 at the XVI International AIDS Conference, Toronto, Ontario, Canada.)

MATERIALS AND METHODS

Participants and sample collection.

Women at high risk for heterosexual acquisition of HIV were recruited as part of a study of behavioral change resulting from participation in a phase 3 preventive vaccine trial (Centers for Disease Control and Prevention Project Vision). Women at low risk were recruited independently. The protocol was approved by the local institutional review board, and written informed consent was obtained in accordance with institutional review board policies for both cohorts. All participants were HIV seronegative and had never injected drugs. High-risk participants (n = 62) had to have had at least one HIV-seropositive sex partner or at least two of the following risk factors: crack cocaine use during the last 6 months; exchange of sex for money, drugs, or shelter during the last 6 months; at least five sex partners during the last 6 months; or a history of sexually transmitted diseases during the last year. Low-risk participants (n = 33) had to have had no HIV-seropositive sex partners; never to have used crack cocaine; never to have exchanged sex for money, drugs, or shelter; to have had no more than one sex partner during the last 6 months and no more than five sex partners during the last 5 years; and to have no history of sexually transmitted diseases. Participants were given physical examinations. For all subjects, a pelvic examination was performed and vaginal secretions were collected from the posterior fornix by use of a swab for the preparation of a wet-mount slide. For the Lf and SLPI studies, only baseline samples were used. An endocervical sponge (Weck-Cel; Medtronic, Jacksonville, FL) was inserted into the cervical os for 1 min. The fluid was removed from the sponge by centrifugation and aliquoted. These samples were used for RANTES measurements and included baseline samples. Where BV was present, treatment was given and posttreatment samples were collected for RANTES testing. CVL fluid samples were collected after the swab by directing a 10-ml stream of sterile normal saline at the cervical os and the endocervix. Fluid was aspirated and centrifuged to pellet cells. For these experiments, clarified CVL fluid was used. Fluid pooled in the posterior fornix of the vagina was aspirated and processed within 2 h of collection. The samples were evaluated for the presence of blood by ChemStrip analysis (Roche Diagnostics). Seminal p30 was detected with the Abacard test kit. The CVL fluid samples were centrifuged at 600 × g for 15 min, and the supernatant was frozen at −70°C. All of the samples used in this study were screened for Chlamydia infection and gonorrhea as determined by Gen-Probe and BDProbeTec tests (Gen-Probe Inc., San Diego, CA; Becton Dickinson, Sparks, MD). Samples were screened for BV by use of the criteria of Amsel et al. (3), which require the presence of three of the following four factors: (i) a vaginal pH above 4.5; (ii) a thin, homogeneous vaginal discharge; (iii) a positive potassium hydroxide odor; and (iv) clue cells on a saline wet mount (1).

Wet-mount slides were prepared in saline for the diagnosis of Trichomonas vaginalis.

Lf and SLPI assays.

Lf, SLPI, and RANTES levels were measured with commercial enzyme-linked immunosorbent assay kits. The sensitivity of the Lf kit (Calbiochem, EMD Biosciences, San Diego, CA) is >1 ng/ml. Those of the SLPI and RANTES kits (R&D Systems, Minneapolis, MN) are 25 pg/ml (range exceeds 50,000 pg/ml) and 2.0 pg/ml, (range, 2,000 pg/ml), respectively.

Statistical methods.

Summary statistics were obtained for Lf, SLPI, and risk factors that characterize the low- and high-risk groups (the cohort identity) and other measurements such as erythrocyte and leukocyte counts. The high-risk and low-risk groups were compared for both Lf and SLPI concentrations by the t test. Associations between the response variables (Lf and SLPI) and risk factors and other measurements were examined individually with linear regression models before and after adjusting for the cohort effect. Multivariate linear-regression models were used to examine the association between the response variables (Lf and SLPI, respectively) and the cohort after adjusting for other covariates. The stepwise variable selection procedure was used to find the final multivariate linear models. Analysis of the RANTES data was done by using the random-effect model for repeated measures.

RESULTS

Two cohorts were recruited for this study, 62 high-risk women and 33 low-risk women. Their demographic data have been published elsewhere and can be found in Table Table11 (15). Semen was detected in eight samples but was not associated with any of the findings studied, so these samples were included in the analyses (Table (Table22).

TABLE 1.
Summary of demographics, sexual partners, and practices of study participants
TABLE 2.
Effects of BV and vaginal leukocytes on SLPI and Lf levels

The mean Lf concentration in the high-risk group was 204 ng/ml (standard deviation = 75 ng/ml; range, 19 to 371 ng/ml), which was significantly higher than the mean in the low-risk cohort, which was 160 ng/ml (standard deviation = 70 ng/ml; range, 13 to 252 ng/ml; Fig. Fig.1A)1A) (P = 0.007). The mean SLPI concentration in the high-risk group was 9,987 pg/ml (standard deviation = 3,292 pg/ml; range, 1,832 to 21,469 pg/ml), which did not differ significantly from that of the low-risk cohort, with a mean concentration of 9,257 pg/ml (standard deviation = 1,892 pg/ml; range, 4,670 to 11,727 pg/ml; Fig. Fig.2A).2A). Subgroups of 26 high-risk and 11 low-risk women were also tested for RANTES levels. For these studies, paired endocervical fluid samples collected before and after BV treatment were studied. Since BV was absent in the low-risk women, we compared posttreatment samples from the high-risk cohort with low-risk samples. The RANTES levels in cervical fluid were 316.6 ± 175 pg/ml in the low-risk women. In the high-risk women with BV, the RANTES level was 2,428.4 ± 9,307.1 pg/ml, and posttreatment it was 331.3 ± 632.0 pg/ml (Fig. (Fig.3).3). The difference was significant (P = 0.05). However, 17 women had a reduction in RANTES levels with treatment, compared to 9 who had increased RANTES levels following treatment. There was no significant difference between the posttreatment levels in the high-risk and low-risk groups. However, the high-risk group is represented by women with a range of risk behaviors. We further defined a higher-risk group of women who reported having had >10 partners in 6 months and using condoms sometimes or never. When we compared these women to the remainder of the high-risk cohort, they had significantly higher RANTES levels (P = 0.03).

FIG. 1.
Effects of cohort and BV on Lf concentrations in CVL fluid. The data shown are means and 95% confidence intervals (error bars). (A) For the cohort effect, the P value is 0.007. (B) For the BV effect, the P value is 0.004.
FIG. 2.
Effects of cohort and BV on SLPI concentrations in CVL fluid. The data shown are means and 95% confidence intervals (error bars). (A) For the cohort effect, the P value shows no statistical significance. (B) For the BV effect, the P value is 0.04. ...
FIG. 3.
The mean RANTES levels of the pre- and posttreatment subgroups were 2,428.4 ± 9,307.1 pg/ml and 331.3 ± 632.0 pg/ml (P = 0.05), respectively. Seventeen women had decreased RANTES levels posttreatment, and nine had increased levels. ...

The concentrations of SLPI and Lf in the presence or absence of BV or vaginal leukocytes are given in Table Table2.2. It appears that the presence of BV decreases the mean SLPI concentration (P = 0.04; Fig. Fig.2B)2B) but increases the mean Lf concentration (P = 0.004; Fig. Fig.1B).1B). In addition, increased levels of leukocytes are associated with a decrease in SLPI (statistically insignificant, P = 0.25) and an increase in Lf (P = 0.0002).

A number of other cofactors that might influence the concentrations of SLPI and Lf were analyzed. With the exception of BV, none of the other risk factors studied was significantly associated with the concentration of SLPI (data not shown). On the other hand, as shown in Table Table3,3, several risk factors, when considered individually, are significantly associated with the concentration of Lf. These include BV, the presence of red blood cells, the presence of leukocytes, and vaginitis, which includes both BV and Trichomonas infection. The phase of the menstrual cycle was not associated with either SLPI or Lf. In the multivariate analysis, after adjustment for the risk group, only the levels of leukocytes in the CVL fluid specimen remained strongly associated with the concentration of Lf (P < 0.0001). None of the other risk factors, including BV, were still associated with the concentration of Lf at a significance level of 0.05. In general, this suggests that most of the effects of the risk factors are explained by the risk group and the levels of leukocytes. The effects of leukocytes on the Lf concentration were similar for both the low- and high-risk groups (Table (Table3,3, analysis 2).

TABLE 3.
Association between Lf and other factors by linear regression modelsa

Several risk behaviors were positively associated with Lf concentrations as part of the overall cohort effect but were not independently associated with the Lf concentration after adjustment for the cohort effect. It appears that the effect of risky behavior on Lf is largely accounted for by the variable “exchange of sex for drugs, money, or shelter” when the effect of leukocytes in the CVL fluid specimen is adjusted for. We collected data on contraceptive and antibiotic use. Only seven participants used hormonal contraceptives. There was no association between type of contraception and either SLPI or Lf. None of the participants reported antibiotic use at the time these samples were taken.

The concentration of SLPI in the CVL fluid samples was not associated with risk behavior. However, the presence of bacterial vaginosis was negatively associated with the SPLI concentration (P = 0.04).

DISCUSSION

This study of the innate immune factors SLPI, Lf, and RANTES in the genital secretions of women at high risk for HIV infection but who remain seronegative, compared to a low-risk control group, was able to demonstrate an association of Lf levels with risk behavior, but no similar association existed for SLPI levels with the risk group. RANTES levels were not associated with the risk group, but on further analysis of the high-risk cohort, there did appear to be a positive relationship between RANTES levels and risk behavior. These disparate results for RANTES may reflect a smaller subgroup of the cohort in which this was studied, as well as the use of cervical sponge samples rather than CVL fluid samples. Additionally, we studied pre- and post-BV treatment samples rather than only baseline samples. These paired samples demonstrated a significant effect of BV treatment on a reduction in RANTES levels. This effect was by no means universal, however, with a third of the women experiencing an increase in RANTES after BV treatment. Other reports of exposed, uninfected women have demonstrated higher levels of RANTES compared to low-risk or HIV-infected women (12, 14). The methods used differed somewhat from those of the present study. Our finding that RANTES levels increased with risk behavior in the high-risk cohort is consistent with these previous reports. Because we chose to study paired samples pre- and posttreatment of BV, potential confounders were better controlled. However, selection bias may exist because the high-risk group does not represent the general population. The effect of BV treatment in the paired samples indicates that BV may raise RANTES levels. Since BV is a highly prevalent infection in high-risk women (24% of this cohort), it may be that the higher RANTES levels seen in other studies may, at least in part, be attributable to coexisting BV or another infection, in addition to the risk group.

None of the specific risk behaviors which define the high-risk group were found to be independently associated with Lf. Further analysis of the association with other measured factors after controlling for behavioral risk demonstrates a strong association with the presence of leukocytes, as well as erythrocytes. Since Lf is a product of leukocytes, this association is expected and consistent with the high level of vaginal leukocytes we have observed in high-risk women, both with and without a specific diagnosis of vaginosis or vaginitis (16, 26). However, there was also an association of Lf with bacterial vaginosis, which was independent of vaginal leukocytosis, unlike Trichomonas infection. Several reports have described the effect of BV on neutrophil numbers and activation and indicated no substantial difference in neutrophil numbers in women with BV compared to healthy controls but a much higher level of inflammatory cytokines in the presence of BV (6). There are numerous studies describing the presence of Lf in neutrophilic granules, so it could be inferred that higher levels of neutrophil activation could lead to their degranulation and subsequent release of Lf (1, 17).

There have been several reports of BV as a risk factor for HIV transmission in women (22, 25) suggesting that the antiviral effect observed with Lf is not adequate to counter the enhancing effect of BV on transmission. The vaginal milieu is complex, and any effect that Lf and/or SLPI may have on HIV transmission must be seen in the context of a multifactorial process in which these two factors may be involved.

While no association was seen between SLPI levels and the risk group, there was a significantly lower level of SLPI in women with coexisting BV than in those without BV. In the oral cavity and the genital tract, SLPI, a product of epithelial cells and phagocytes, is degraded by cysteine proteases such as cathepsin B, which are increased in inflammatory tissue (8, 9). One role of SLPI is to inactivate elastases, which can damage mucosal surfaces, so it is possible that the inflammation induced by BV may release cysteine proteases which degrade SLPI, as has been demonstrated with Trichomonas infection (9). Alternatively, the organisms or by-products of BV may down-regulate SLPI production or release. If SLPI does have an in vivo effect on HIV infection, this finding is consistent with the enhancing effect of BV on transmission, at least in part, through an effect on the SLPI concentration. Further prospective studies are needed to elucidate the role, if any, of these innate factors in the heterosexual transmission of HIV-1.

Acknowledgments

The work described herein was supported by National Institute of Child Health and Human Development program project HD40539 and Centers for Disease Control and Prevention vision study contract 200-2000-00051.

We do not have a commercial association that would pose a conflict of interest with this work.

Footnotes

[down-pointing small open triangle]Published ahead of print on 1 August 2007.

REFERENCES

1. Afeltra, A., D. Caccavo, G. M. Ferri, M. A. Addessi, F. G. De Rosa, A. Amoroso, and L. Bonomo. 1997. Expression of lactoferrin on human granulocytes: analysis with polyclonal and monoclonal antibodies. Clin. Exp. Immunol. 109279-285. [PMC free article] [PubMed]
2. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 2721955-1958. [PubMed]
3. Amsel, R., P. A. Totten, C. A. Spiegel, K. C. Chen, D. Eschenbach, and K. K. Holmes. 1983. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med. 7414-22. [PubMed]
4. Berkhout, B., R. Floris, I. Recio, and S. Visser. 2004. The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals 17291-294. [PubMed]
5. Capobianchi, M. R., I. Abbate, G. Antonelli, O. Turriziani, A. Dolei, and F. Dianzani. 1998. Inhibition of HIV type 1 BaL replication by MIP-1α, MIP-1β, and RANTES in macrophages. AIDS Res. Hum. Retrovir. 14233-240. [PubMed]
6. Cauci, S., S. Guaschino, D. De Aloysio, S. Driussi, D. De Santo, P. Penacchioni, and F. Quadrifoglio. 2003. Interrelationships of interleukin-8 with interleukin-1β and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol. Hum. Reprod. 953-58. [PubMed]
7. Cocchi, F., A. L. DeVico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 2701811-1815. [PubMed]
8. Cox, S. W., E. M. Rodriguez-Gonzalez, V. Booth, and B. M. Eley. 2006. Secretory leukocyte protease inhibitor and its potential interactions with elastase and cathepsin B in gingival crevicular fluid and saliva from patients with chronic periodontitis. J. Periodontal Res. 41477-485. [PubMed]
9. Draper, D., W. Donohoe, L. Mortimer, and R. P. Heine. 1998. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J. Infect. Dis. 178815-819. [PubMed]
10. Farquhar, C., T. C. VanCott, D. A. Mbori-Ngacha, L. Horani, R. K. Bosire, J. K. Kreiss, B. A. Richardson, and G. C. John-Stewart. 2002. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J. Infect. Dis. 1861173-1176. [PMC free article] [PubMed]
11. Florisa, R., I. Recio, B. Berkhout, and S. Visser. 2003. Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr. Pharm. Des. 91257-1275. [PubMed]
12. Hirbod, T., J. Nilsson, S. Andersson, C. Uberti-Foppa, D. Ferrari, M. Manghi, J. Andersson, L. Lopalco, and K. Broliden. 2006. Upregulation of interferon-alpha and regulated on activation, normal T cell expressed and secreted in the cervix of HIV-1-seronegative women with high-risk behavior. J. Acquir. Immune Defic. Syndr. 43137-143. [PubMed]
13. Hocini, H., P. Becquart, H. Bouhlal, H. Adle-Biassette, M. D. Kazatchkine, and L. Belec. 2000. Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin. Diagn. Lab. Immunol. 7515-518. [PMC free article] [PubMed]
14. Iqbal, S. M., T. B. Ball, J. Kimani, P. Kiama, P. Thottingal, J. E. Embree, K. R. Fowke, and F. A. Plummer. 2005. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J. Infect. Dis. 192728-738. [PubMed]
15. Jendrysik, M. A., M. Ghassemi, P. J. Graham, L. A. Boksa, P. R. Williamson, and R. M. Novak. 2005. Human cervicovaginal lavage fluid contains an inhibitor of HIV binding to dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J. Infect. Dis. 192630-639. [PubMed]
16. King, A. E., H. O. Critchley, and R. W. Kelly. 2003. Innate immune defences in the human endometrium. Reprod. Biol. Endocrinol. 1116. [PMC free article] [PubMed]
17. Konttinen, Y. T., and S. Reitamo. 1979. Localization of lactoferrin in polymorphonuclear neutrophil leucocytes. Br. J. Haematol. 43481. [PubMed]
18. Ma, G., T. Greenwell-Wild, K. Lei, W. Jin, J. Swisher, N. Hardegen, C. T. Wild, and S. M. Wahl. 2004. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med. 2001337-1346. [PMC free article] [PubMed]
19. McNeely, T. B., M. Dealy, D. J. Dripps, J. M. Orenstein, S. P. Eisenberg, and S. M. Wahl. 1995. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Investig. 96456-464. [PMC free article] [PubMed]
20. McNeely, T. B., D. C. Shugars, M. Rosendahl, C. Tucker, S. P. Eisenberg, and S. M. Wahl. 1997. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 901141-1149. [PubMed]
21. Moriuchi, M., and H. Moriuchi. 2001. A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J. Immunol. 1664231-4236. [PubMed]
22. Sewankambo, N., R. H. Gray, M. J. Wawer, L. Paxton, D. McNaim, F. Wabwire-Mangen, D. Serwadda, C. Li, N. Kiwanuka, S. L. Hillier, L. Rabe, C. A. Gaydos, T. C. Quinn, and J. Konde-Lule. 1997. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350546-550. (Erratum, 350:1036, 1997.) [PubMed]
23. Shine, N. R., S. C. Wang, K. Konopka, E. A. Burks, N. Duzgunes, and C. P. Whitman. 2002. Secretory leukocyte protease inhibitor: inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein. Bioorg. Chem. 30249-263. [PubMed]
24. Skott, P., E. Lucht, M. Ehnlund, and E. Bjorling. 2002. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism. Oral Dis. 8160-167. [PubMed]
25. Taha, T. E., R. H. Gray, N. I. Kumwenda, D. R. Hoover, L. A. Mtimavalye, G. N. Liomba, J. D. Chiphangwi, G. A. Dallabetta, and P. G. Miotti. 1999. HIV infection and disturbances of vaginal flora during pregnancy. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 2052-59. [PubMed]
26. Theilgaard-Monch, K., L. C. Jacobsen, T. Rasmussen, C. U. Niemann, L. Udby, R. Borup, M. Gharib, P. D. Arkwright, A. F. Gombart, J. Calafat, B. T. Porse, and N. Borregaard. 2005. Highly glycosylated α1-acid glycoprotein is synthesized in myelocytes, stored in secondary granules, and released by activated neutrophils. J. Leukoc. Biol. 78462-470. [PubMed]
27. Turpin, J. A., C. A. Schaeffer, M. Bu, L. Graham, R. W. Buckheit, Jr., D. Clanton, and W. G. Rice. 1996. Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor. Antiviral Res. 29269-277. [PubMed]
28. Viani, R. M., T. J. Gutteberg, J. L. Lathey, and S. A. Spector. 1999. Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. AIDS 131273-1274. [PubMed]
29. Xu, W., B. He, A. Chiu, A. Chadburn, M. Shan, M. Buldys, A. Ding, D. M. Knowles, P. A. Santini, and A. Cerutti. 2007. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat. Immunol. 8294-303. [PubMed]

Articles from Clinical and Vaccine Immunology : CVI are provided here courtesy of American Society for Microbiology (ASM)
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...